Literature DB >> 29439960

Anidulafungin Pharmacokinetics in Ascites Fluid and Pleural Effusion of Critically Ill Patients.

R Welte1, P Eller2, I Lorenz3, M Joannidis4, R Bellmann5.   

Abstract

Anidulafungin concentrations were quantified with high-pressure liquid chromatography (HPLC) and UV detection of the ascites fluid and pleural effusion of 10 adult critically ill patients. Samples were collected from ascites fluid and from pleural drains or during paracentesis and thoracentesis, respectively. Anidulafungin levels in ascites fluid (0.12 to 0.99 μg/ml) and in pleural effusion (0.32 to 2.02 μg/ml) were below the simultaneous levels in plasma (1.04 to 7.70 and 2.48 to 13.36 μg/ml, respectively) and below the MIC values for several pathogenic Candida strains.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  antifungal target-site pharmacokinetics; echinocandins; fungal peritonitis; fungal thoracic empyema; invasive candidiasis; invasive fungal disease; tissue distribution

Mesh：

Substances：

Year:  2018        PMID： 29439960      PMCID： PMC5913985          DOI： 10.1128/AAC.02326-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Levels of amphotericin B lipid formulations in ascites.

Authors:  Stefan Weiler; Rosa Bellmann-Weiler; Stefan Dunzendorfer; Michael Joannidis; Romuald Bellmann
Journal:  J Antimicrob Chemother       Date:  2008-07-28       Impact factor: 5.790

2.  Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema.

Authors:  Brad Moriyama; Marisa Ditullio; Eleanor Wilson; Stacey A Henning; Scott R Penzak; Robert L Danner; Gennethel Pennick; Michael G Rinaldi; Adrian M Zelazny; Juan Gea-Banacloche; A John Barrett; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

3.  Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis.

Authors:  Federico Pea; Elda Righi; Piergiorgio Cojutti; Alessia Carnelutti; Umberto Baccarani; Giorgio Soardo; Matteo Bassetti
Journal:  J Antimicrob Chemother       Date:  2014-05-15       Impact factor: 5.790

4.  In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Authors:  D Andes; D J Diekema; M A Pfaller; J Bohrmuller; K Marchillo; A Lepak
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

5.  Fungal empyema thoracis in cancer patients.

Authors:  Masayuki Nigo; Macarena R Vial; Jose M Munita; Ying Jiang; Jeffrey Tarrand; Carlos A Jimenez; Dimitrios P Kontoyiannis
Journal:  J Infect       Date:  2016-03-02       Impact factor: 6.072

6.  Determination of micafungin and anidulafungin in human plasma: UV- or mass spectrometric quantification?

Authors:  Jens Martens-Lobenhoffer; Victoria Rupprecht; Stefanie M Bode-Böger
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-05-30       Impact factor: 3.205

7.  Distribution of micafungin in the tissue fluids of patients with invasive fungal infections.

Authors:  Noriaki Yamada; Keisuke Kumada; Satoshi Kishino; Nobuo Mochizuki; Keiko Ohno; Shinji Ogura
Journal:  J Infect Chemother       Date:  2011-05-03       Impact factor: 2.211

8.  Anidulafungin versus fluconazole for invasive candidiasis.

Authors:  Annette C Reboli; Coleman Rotstein; Peter G Pappas; Stanley W Chapman; Daniel H Kett; Deepali Kumar; Robert Betts; Michele Wible; Beth P Goldstein; Jennifer Schranz; David S Krause; Thomas J Walsh
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245

9.  Penetration of amphotericin B lipid formulations into pleural effusion.

Authors:  Stefan Weiler; Rosa Bellmann-Weiler; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

10.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079
View more
  4 in total

1.  Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis.

Authors:  Arthur W Baker; Eileen K Maziarz; Christopher J Arnold; Melissa D Johnson; Adrienne D Workman; John M Reynolds; John R Perfect; Barbara D Alexander
Journal:  Clin Infect Dis       Date:  2020-01-01       Impact factor: 9.079

2.  Human Tissue Distribution of Anidulafungin and Micafungin.

Authors:  Jana Marx; René Welte; Tiziana Gasperetti; Patrizia Moser; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

3.  Pharmacokinetics and Antifungal Activity of Echinocandins in Ascites Fluid of Critically Ill Patients.

Authors:  René Welte; Herbert Oberacher; Tiziana Gasperetti; Hartwig Pfisterer; Andrea Griesmacher; Tobias Santner; Cornelia Lass-Flörl; Caroline Hörtnagl; Sandra Leitner-Rupprich; Maria Aigner; Ingo Lorenz; Stefan Schmid; Michael Edlinger; Philipp Eller; Daniel Dankl; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

4.  Candida Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes.

Authors:  Suheyla S Senger; George R Thompson; Palash Samanta; Jillian Ahrens; Cornelius J Clancy; M Hong Nguyen
Journal:  Open Forum Infect Dis       Date:  2021-04-17       Impact factor: 3.835
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.